环孢素A联合糖皮质激素治疗大量蛋白尿免疫球蛋白A肾病的临床疗效及安全性

发布时间：2018-09-10 16:46

【摘要】：目的分析探究在大量蛋白尿免疫球蛋白A肾病的治疗过程中应用环孢素A联合糖皮质激素的临床效果和安全性。方法随机选取我院2015年6月-2017年6月收治的大量蛋白尿免疫球蛋白A肾病患者40例,将其随机分成两组,即对照组和观察组,各20例,在对照组患者中采用甲泼尼龙进行治疗,而在观察组患者则采用对照组药物的同时采用环孢素A,对比分析两组患者的治疗效果以及不良反应发生率。结果两组患者在进行为期24周的治疗后,相较于对照组,观察组患者的病情完全缓解率较高,差异具有统计学意义(P0.05);而两组患者在接受治疗两周后,观察组患者的尿蛋白含量要明显低于对照组,差异具有统计学意义(P0.05);在不良反应的发生率方面,对照组与观察组差异不具备统计学意义(P0.05)。结论在大量蛋白尿免疫球蛋白A肾病的治疗过程中应用环孢素A联合糖皮质激素,不仅治疗效果显著,而且不良反应发生率较低,临床应用价值较高。
[Abstract]:Objective to investigate the clinical efficacy and safety of cyclosporine A combined with glucocorticoid in the treatment of massive proteinuria immunoglobulin A nephropathy. Methods from June 2015 to June 2017, 40 patients with proteinuria immunoglobulin A nephropathy were randomly divided into two groups: control group (n = 20) and observation group (n = 20). Methylprednisolone was used in the control group. The patients in the observation group were treated with cyclosporine A as well as the control group. The therapeutic effect and the incidence of adverse reactions were compared between the two groups. Results after 24 weeks of treatment, the complete remission rate of patients in the observation group was higher than that in the control group (P0.05). The urine protein content in the observation group was significantly lower than that in the control group, the difference was statistically significant (P0.05); in the incidence of adverse reactions, the difference between the control group and the observation group was not statistically significant (P0.05). Conclusion the application of cyclosporine A combined with glucocorticoid in the treatment of massive proteinuria immunoglobulin A nephropathy is not only effective, but also has lower incidence of adverse reactions and higher clinical application value.
【作者单位】：内蒙古民族大学附属医院;
【分类号】：R692.31

【相似文献】